AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01523418 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) \& 5 weeks (THR)
Study NCT00462306 — intervention group
Intervention type: PROCEDURE
Intervention: Survey: Berlin questionnaire
Description: Completion of questionnaire
Study NCT01329627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/doxorubicin/cyclophosphamide
Description: Metronomic chemotherapy as described below:~1. Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~2. Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Study NCT01329627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/doxorubicin/cyclophosphamide
Description: Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks.
Study NCT00503100 — intervention group
Intervention type: DEVICE
Intervention: Thermal stimulation
Description: Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
Study NCT03155724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPole Pacing
Description: CRT non-responders are programmed with MultiPole pacing ON.
Study NCT02111330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509
Study NCT04765787 — intervention group
Intervention type: DRUG
Intervention: Combination of Paracetamol 650mg + Orphenadrine 50mg
Description: In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
Study NCT03182361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
Description: Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
Study NCT04385589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.
Study NCT04385589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: insulin
Study NCT04385589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin
Description: insulin
Study NCT01757444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP - A40
Description: Patients receiving BiPAP AVAPS - AE ventilatory mode at home
Study NCT02130219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure measurement
Description: The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
Study NCT02111330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01693549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study NCT01125982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
Study NCT01125982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
Study NCT02169986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic reminders
Study NCT01757444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP - ST
Description: Patients receiving BiPAP- ST mode at home.
Study NCT01462032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Executive, Attention and Motor Skills (TEAMS)
Description: Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
Study NCT01462032 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent support and education
Description: Parents will participate in groups designed to provide information about ADHD and support for working with their child.
Study NCT00495105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two Servings of Dairy Snacks
Description: 2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
Study NCT01960777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Onstep
Study NCT01960777 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair
Study NCT02888873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups.
Study NCT02888873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma Classic
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups.
Study NCT00659178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Description: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Study NCT02130219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI/CT
Description: 1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume.
Study NCT01302860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study NCT03111511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol
Description: A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
Study NCT03111511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg orally on Days 1 and 21.
Study NCT03111511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
Study NCT01675245 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
Study NCT02248181 — intervention group
Intervention type: DRUG
Intervention: Pramipexole
Study NCT01775124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg Ranibizumab
Study NCT02130219 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture and cerebrospinal fluid pressure measurement
Description: Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
Study NCT03770819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.
Study NCT00250341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR
Description: 480 mcg
Study NCT02440945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of blood
Description: Blood test on blotting paper DBS (for the patients recruting)
Study NCT01757431 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eculizumab
Study NCT02806648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib
Study NCT00502463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² day 1
Study NCT00502463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² day 1
Study NCT00250341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair
Description: 250/50 mcg
Study NCT00250341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Servent Diskus
Description: 50 mcg
Study NCT03770819 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.
Study NCT03770819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.
Study NCT01566370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
Study NCT01566370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02868944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).
Study NCT00502463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750mg/m²/day day 1-5
Study NCT00502463 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks
Study NCT00502463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250mg/m²/week after an initial loading dose of 400mg/m²
Study NCT00439231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
Study NCT01466101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Administration of placebo
Study NCT01466101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin administration
Description: Administration of pregabalin
Study NCT02868944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.
Study NCT00566826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient support sessions
Description: Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
Study NCT00598936 — intervention group
Intervention type: DEVICE
Intervention: CDI 1000 COM and INVOS 5100
Description: CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
Study NCT01176734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS-Device
Description: Active treatment with the t-VNS device.
Study NCT00566826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes standard care for TKR surgery rehabilitation.
Study NCT04215536 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin dispensing claim is exposure
Study NCT04215536 — intervention group
Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim is reference
Study NCT03070080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid strategy
Description: restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
Study NCT03070080 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative fluid strategy
Description: conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
Study NCT01484210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpenhaler active - Diskus placebo
Description: randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
Study NCT03917797 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment
Description: Umbilical cord-derived Mesenchymal Stromal Cell
Study NCT03917797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
Study NCT03917797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
Study NCT03917797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MSC infusion vehicle
Study NCT02588326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 1
Description: Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
Study NCT02588326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 2
Description: Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
Study NCT00431626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (Avodart)
Study NCT00431626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo before and after treatment of TURP
Study NCT01347528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence Support System (MASS)
Description: The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
Study NCT01936714 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Study NCT02346045 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Renal sympathetic denervation
Description: In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~1. After femoral puncture guiding catheter is engaged in renal artery~2. Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~3. 4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed
Study NCT00895154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Tutoring
Description: Participants will be tutored for approximately 8-10 hours per month during the school year.
Study NCT00895154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Tutoring
Description: Participants will be tutored for approximately 8-10 hours per month during the school year.
Study NCT00895154 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training
Description: Participants will receive memory training for approximately 8-10 hours per month during the school year.
Study NCT01993927 — intervention group
Intervention type: DRUG
Intervention: Voglibose
Description: Voglibose Tablets / Voglibose OD Tablets
Study NCT03702231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine Recombinant, Adjuvanted
Description: A series of 2 doses of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) will be given on a 0- and 3-month schedule by intramuscular injection.
Study NCT03095677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program of training with exercises including apnea
Description: 16 training session on cycle ergometry with exercises including apneas.
Study NCT03095677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Program of training with exercises without apnea
Description: 16 training session on cycle ergometry with exercises without apnea
Study NCT01353768 — intervention group
Intervention type: OTHER
Intervention: retrospective chart review
Description: retrospective chart review
Study NCT04018573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATHS Sexual Communication Toolkit
Description: The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.